Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes

被引：0
作者：
Wei, Andrew H. [1 ,2 ,3 ]
Seymour, John F. [1 ,2 ]
机构：
[1] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 03期
基金：
英国医学研究理事会;
关键词：
myelodysplastic syndromes; Hypomethylating agents; lenalidomide; CONVENTIONAL CARE REGIMENS; AZACITIDINE; LENALIDOMIDE; CLASSIFICATION; COMBINATION;
D O I：
10.1111/bjh.18240
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hypomethylating agents remain the current standard of care for patients with higher-risk myelodysplastic syndromes. Ades et al. report outcomes from a randomised 'pick-a-winner' study design that examined the addition of either lenalidomide, valproic acid or idarubicin in combination with azacitidine, compared to azacitidine alone. Commentary on: Ades et al. A randomised phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS: GFM's 'pick a winner' trial, with the impact of somatic mutations. Br J Haematol 2022 (Online ahead of print). doi: 10.1111/bjh.18193.
引用
收藏
页码：415 / 418
页数：4
相关论文
共 16 条
  • [1] A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations
    Ades, Lionel
    Duployez, Nicolas
    Guerci-Bresler, Agnes
    Laribi, Kamel
    Peterlin, Pierre
    Vey, Norbert
    Thepot, Sylvain
    Wickenhauser, Stefan
    Zerazhi, Hacene
    Stamatoullas, Aspassia
    Wattel, Eric
    Recher, Christian
    Toma, Andrea
    Dimicoli-Salazar, Sophie
    Braun, Thorsten
    Beyne-Rauzy, Odile
    Marolleau, Jean-Pierre
    Cheze, Stephane
    Park, Sophie
    Cluzeau, Thomas
    Nimubona, Stanislas
    Bordessoule, Dominique
    Benramdane, Riad
    Quesnel, Bruno
    Ame, Shanti
    de Botton, Stephane
    Chermat, Fathia
    Preudhomme, Claude
    Chevret, Sylvie
    Fenaux, Pierre
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (03) : 535 - 544
  • [2] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
    Arber, Daniel A.
    Orazi, Attilio
    Hasserjian, Robert
    Thiele, Jurgen
    Borowitz, Michael J.
    Le Beau, Michelle M.
    Bloomfield, Clara D.
    Cazzola, Mario
    Vardiman, James W.
    [J]. BLOOD, 2016, 127 (20) : 2391 - 2405
  • [3] BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x
  • [4] Bernard E, 2021, MOL INT PROGNOSIS SC
  • [5] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    Fenaux, Pierre
    Mufti, Ghulam J.
    Hellstrom-Lindberg, Eva
    Santini, Valeria
    Finelli, Carlo
    Giagounidis, Aristoteles
    Schoch, Robert
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan
    Gore, Steven D.
    Seymour, John F.
    Bennett, John M.
    Byrd, John
    Backstrom, Jay
    Zimmerman, Linda
    McKenzie, David
    Beach, C. L.
    Silverman, Lewis R.
    [J]. LANCET ONCOLOGY, 2009, 10 (03) : 223 - 232
  • [6] A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
    Gore, Steven D.
    Fenaux, Pierre
    Santini, Valeria
    Bennett, John M.
    Silverman, Lewis R.
    Seymour, John F.
    Hellstrom-Lindberg, Eva
    Swern, Arlene S.
    Beach, Charles. L.
    List, Alan. F.
    [J]. HAEMATOLOGICA, 2013, 98 (07) : 1067 - 1072
  • [7] Revised International Prognostic Scoring System for Myelodysplastic Syndromes
    Greenberg, Peter L.
    Tuechler, Heinz
    Schanz, Julie
    Sanz, Guillermo
    Garcia-Manero, Guillermo
    Sole, Francesc
    Bennett, John M.
    Bowen, David
    Fenaux, Pierre
    Dreyfus, Francois
    Kantarjian, Hagop
    Kuendgen, Andrea
    Levis, Alessandro
    Malcovati, Luca
    Cazzola, Mario
    Cermak, Jaroslav
    Fonatsch, Christa
    Le Beau, Michelle M.
    Slovak, Marilyn L.
    Krieger, Otto
    Luebbert, Michael
    Maciejewski, Jaroslaw
    Magalhaes, Silvia M. M.
    Miyazaki, Yasushi
    Pfeilstoecker, Michael
    Sekeres, Mikkael
    Sperr, Wolfgang R.
    Stauder, Reinhard
    Tauro, Sudhir
    Valent, Peter
    Vallespi, Teresa
    van de Loosdrecht, Arjan A.
    Germing, Ulrich
    Haase, Detlef
    [J]. BLOOD, 2012, 120 (12) : 2454 - 2465
  • [8] Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
    Grob, Tim
    Al Hinai, Adil S. A.
    Sanders, Mathijs A.
    Kavelaars, Francois G.
    Rijken, Melissa
    Gradowska, Patrycja L.
    Biemond, Bart J.
    Breems, Dimitri A.
    Maertens, Johan
    Kooy, Marinus van Marwijk
    Pabst, Thomas
    de Weerdt, Okke
    Ossenkoppele, Gert J.
    van de Loosdrecht, Arjan A.
    Huls, Gerwin A.
    Cornelissen, Jan J.
    Beverloo, H. Berna
    Lowenberg, Bob
    Jongen-Lavrencic, Mojca
    Valk, Peter J. M.
    [J]. BLOOD, 2022, 139 (15) : 2347 - 2354
  • [9] Applicability of a "Pick a Winner" trial design to acute myeloid leukemia
    Hills, Robert K.
    Burnett, Alan K.
    [J]. BLOOD, 2011, 118 (09) : 2389 - 2394
  • [10] Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
    Kenealy, Melita
    Hertzberg, Mark
    Benson, Warwick
    Taylor, Kerry
    Cunningham, Ilona
    Stevenson, Will
    Hiwase, Devendra
    Eek, Richard
    Zantomio, Daniela
    Jong, Steve
    Wall, Meaghan
    Blombery, Piers
    Gerber, Tracey
    Debrincat, Marlyse
    Zannino, Diana
    Seymour, John F.
    [J]. HAEMATOLOGICA, 2019, 104 (04) : 700 - 709
12